Smith & Nephew stock edges higher after recent earnings and guidance

Published on 09/06/2026 at 15:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Smith & Nephew stock has firmed around its New York listing as investors weigh the latest half-year figures, guidance and valuation after a double-digit revenue increase.

Schwarzweiß-Reportage zeigt ein Operationsteam mit Instrumenten im Saal — Smith & Nephew plc (ISIN GB0009223206) liefert Instrumente für Operationssäle, dokumentiert als authentische Schwarzweiß-Reportage, Illustration mit AI erstellt.

Smith & Nephew stock (ISIN GB0009223206) is trading close to 29.00 dollars on the New York Stock Exchange as of September 4, 2026, after a recent move higher that leaves the shares around 11.9 percent below their level a year ago according to MarketBeat data.

Recent figures and margin trend

According to recent earnings information compiled by MarketBeat, Smith & Nephew reported revenue of about 5.60 billion dollars for its latest fiscal year, representing a mid-single-digit percentage increase compared with the previous year and underlining the company’s gradual growth trajectory.

The same overview indicates that earnings per share for the most recently reported period stood in the low dollar range, with adjusted profitability improving versus the prior year as management focused on cost efficiency and portfolio mix. This improvement in EPS and margin, even if modest, is an important factor for investors assessing whether the current valuation fairly reflects the company’s progress.

Valuation and performance context

MarketBeat’s snapshot shows Smith & Nephew stock at 28.91 dollars as of September 4, 2026, with the shares down 11.9 percent over the last twelve months, illustrating that the market remains cautious despite revenue growth and operational improvements.

On standard valuation metrics cited in the same overview, including the price-earnings multiple based on recent earnings, Smith & Nephew trades at a level that reflects its mature profile and competitive medical technology positioning, but does not price in aggressive growth expectations.

Go deeper

More on Smith & Nephew as an investment

For readers who want to explore longer-term performance, fundamentals and news on Smith & Nephew, the overview of articles and market data linked here provides additional depth.

All news on Smith & Nephew Investor Relations

Orthopedic and wound care portfolio

Smith & Nephew is best known for its orthopedic reconstruction and sports medicine devices as well as advanced wound care products, which together form a diversified medical technology portfolio.

Stock price snapshot and investor view

Based on recent data as of September 4, 2026 from Yahoo Finance, Smith & Nephew stock last traded around 28.87 dollars on the New York Stock Exchange, only slightly below the 28.91 dollars level indicated by MarketBeat, reflecting a relatively stable price range in recent sessions.